Cancer Vaccines Market Research Report
The cancer vaccines market is projected to reach USD 7.3 billion by 2027, exhibiting a CAGR of 12.6% during the forecast period.
WILMINGTON, DE, UNITED STATES, January 30, 2025 /
EINPresswire.com/ -- The global
cancer vaccines market has experienced significant growth in recent years, driven by increasing cancer incidences, advancements in immunotherapy, and rising awareness about cancer prevention and treatment. As of 2019, the cancer vaccines market was valued at approximately USD 4.18 billion and is projected to reach USD 7.3 billion by 2027, exhibiting a CAGR of 12.6% during the forecast period.
Get Sample PDF Copy Here:
https://www.alliedmarketresearch.com/request-sample/1453
Cancer Vaccines Market Growth Factors
Several factors contribute to the growth of the cancer vaccines market:
- Increasing Cancer Incidences: The rising number of cancer cases globally is a significant driver for the demand for effective preventive and therapeutic vaccines.
- Advancements in Immunotherapy: Innovations in immunotherapy, including the development of personalized cancer vaccines, have enhanced treatment efficacy and expanded market opportunities.
- Government Initiatives and Funding: Increased investments and funding from governments and private sectors in cancer research and vaccine development are propelling market growth.
- Rising Awareness and Education: Public awareness campaigns and educational programs about cancer prevention and the benefits of vaccination are driving demand for cancer vaccines.
- Technological Advancements: Continuous research and development in vaccine technology, including the use of mRNA platforms, are leading to more effective and targeted cancer vaccines.
Have Any Query? Ask Our Experts:
https://www.alliedmarketresearch.com/purchase-enquiry/1453
Cancer Vaccines Market Segmentation
The cancer vaccines market is categorized based on technology, type, indication, end user, and region.
By Technology:
- Recombinant Cancer Vaccines: These vaccines are the major revenue contributors, with a significant projected growth during the forecast period. The increase in adoption of recombinant technology and the rise in utilization of recombinant vaccines are key factors driving this segment.
- Dendritic Cells (DC) Cancer Vaccines: Utilize dendritic cells to present cancer antigens to the immune system, enhancing the body's response to cancer cells.
- Antigen/Adjuvant Cancer Vaccines: Combine specific antigens with adjuvants to boost the immune response against cancer cells.
- Viral Vector & DNA Cancer Vaccines: Employ viral vectors or DNA to deliver cancer-specific antigens into the body, stimulating an immune response.
By Type:
- Preventive Cancer Vaccines: Designed to prevent cancer in healthy individuals by stimulating immunity against cancer-causing agents.
- Therapeutic Cancer Vaccines: Aimed at treating existing cancers by enhancing the body's immune response to cancer cells.
By Indication:
- Cervical Cancer: The major shareholder in the global cancer vaccines market, driven by the high prevalence of cervical cancer and the increase in HPV infections.
- Prostate Cancer: Vaccines targeting prostate-specific antigens to stimulate an immune response against prostate cancer cells.
- Others: Includes vaccines targeting various other cancers such as melanoma, lung cancer, and breast cancer.
By End User:
- Pediatric: Cancer vaccines administered to children for prevention or treatment of cancer.
- Adult: Cancer vaccines administered to adults for prevention or treatment of cancer.
By Region:
- North America: Dominates the market due to advanced healthcare infrastructure and high adoption rates of cancer vaccines.
- Europe: Significant market share with increasing government initiatives in cancer research.
- Asia-Pacific: Exhibits the highest CAGR, driven by rising cancer incidences and improving healthcare facilities.
- LAMEA (Latin America, Middle East, and Africa): Emerging markets with growing awareness and healthcare investments.
Key Players in the Cancer Vaccines Market
The cancer vaccines market features several prominent players, including:
- Merck & Co., Inc.
- GlaxoSmithKline plc
- Bavarian Nordic
- Eli Lilly and Company
- Moderna, Inc.
- eTheRNA immunotherapies
- AstraZeneca plc
- Novartis International AG
- Sanofi S.A.
- Pfizer Inc.
The cancer vaccines market is poised for substantial growth, driven by increasing cancer incidences, advancements in immunotherapy, and supportive government initiatives. With ongoing research and development, the market is expected to expand, offering new opportunities for both existing and emerging players in the oncology sector.
Procure Complete Report Here:
https://www.alliedmarketresearch.com/checkout-final/c7ab65485bd397bbdaf81fcfe598ad46?utm_source=Nilesh.Musale
Thanks for reading this article; you can also get an individual chapter-wise sections or region-wise report versions like North America, LATAM, Europe, or Southeast Asia.
About Us:
Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions." AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.
David Correa
Allied Market Research
+ 1 800-792-5285
email us here
Visit us on social media:
Facebook
Twitter
LinkedIn